List of Signifor drug patents
Signifor is owned by Recordati Rare.
Signifor contains Pasireotide Diaspartate.
Signifor has a total of 2 drug patents out of which 0 drug patents have expired.
Signifor was authorised for market use on 14 December, 2012.
Signifor is available in solution;subcutaneous dosage forms.
The generics of Signifor are possible to be released after 14 December, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(2 years from now) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) | |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
Market Authorisation Date: 14 December, 2012
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SIGNIFOR family patents
9
United States
4
European Union
3
Australia
3
Norway
3
Korea, Republic of
3
United Kingdom
2
Israel
2
South Africa
2
Denmark
2
Austria
2
Mexico
2
Hong Kong
2
Slovenia
2
Russia
2
Germany
2
Argentina
2
Brazil
2
Portugal
2
Cyprus
2
Malaysia
2
Spain
2
Peru
2
Poland
2
Taiwan, Province of China
2
China
2
Ecuador
2
Japan
2
Canada
2
New Zealand
1
Slovakia
1
Belgium
1
Hungary
1
Morocco
1
Colombia
1
Croatia
1
Czech Republic
1
Iceland
1
Chile
1
Luxembourg
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic